Halozyme Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +9.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation C+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 22.8x | Better than 34% |
| Forward P/E | 9.3x | Better than 84% |
| Price / Sales | 5.8x | Better than 19% |
| P/E vs own 5-yr range | 65th pctl | Better than 44% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 28.4% | Better than 89% |
| Net income CAGR (3Y) | 16.2% | Better than 68% |
| Free cash flow CAGR (3Y) | 14.9% | Better than 59% |
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 83.6% | Better than 93% |
| Operating margin | 57.5% | Better than 99% |
| Net margin | 22.7% | Better than 83% |
| Return on equity | 153.6% | Better than 98% |
| Return on invested capital | 16.2% | Better than 84% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -15.5% | Better than 39% |
| 6-month return | 33.7% | Better than 91% |
| 12-month return (ex latest month) | 78.6% | Better than 92% |
| Distance below 52-week high | 31.8% | Better than 40% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.7x | Better than 84% |
| Debt to assets | 84.8% | Better than 3% |
| Interest coverage | 26.8x | Better than 85% |
| Free cash flow / net income | 112.6% | Better than 47% |
Analyst View B
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 80.0% | Better than 58% |
| Upside to average target | 37.5% | Better than 57% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 93.04
- Open
- 93.64
- Day range
- 90.79 - 93.64
- Avg price
- 92.07
- Volume
- 1.50M
- Turnover
- 138.37M
- Turnover ratei
- 1.33%
- Volume ratioi
- 0.61
- Amplitudei
- 3.06%
- 52-week rangei
- 61.23 - 134.00
Valuation
- P/Ei
- 35.68
- P/E (TTM)i
- 22.84
- P/Bi
- -188.35
- EPSi
- 2.56
- Book value / shi
- -0.49
- Net profit
- 291.87M
- Net assets
- -55.29M
Share structure
- Market cap
- 10.41B
- Float capi
- 10.30B
- Shares out
- 114.01M
- Float sharesi
- 112.71M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
31.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-2.96M net over the window
Short interest
- Shares short
- 13.65M
- % of floati
- 12.03%
- Days to coveri
- 6.81
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Halozyme Therapeutics (HALO)?
Halozyme Therapeutics last traded at 91.35. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Halozyme Therapeutics's market cap?
About 10.41B.
What is the P/E ratio of Halozyme Therapeutics?
The trailing twelve-month P/E is 22.84, above its own 5-year average of 21.01 — toward the top of its historical range (79.28% percentile). See the Valuation tab for the full history.
Does Halozyme Therapeutics pay a dividend?
Halozyme Therapeutics does not currently pay a regular dividend.
Is Halozyme Therapeutics a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 129.75, which implies 42.0% upside from the current price. This is not investment advice.
What is Halozyme Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Halozyme Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
Halozyme Therapeutics discussion 0 comments